Regeneron Pharmaceuticals (REGN) Rating Grow to Purchase at BidaskClub

Regeneron Pharmaceuticals (REGN) Rating Grow to Purchase at BidaskClub

BidaskClub upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a report published on Friday, October 19th.

Several other research firms have also weighed in on REGN. ValuEngine raised Regeneron Pharmaceuticals from a strong sell rating to a sell rating in a research report on Thursday, September 6th. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research note on Monday, October 1st. They set a neutral rating and a $415.00 target price for the company. Leerink Swann lifted their target price on Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the stock an outperform rating in a research note on Monday, October 1st. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $396.00 to $409.00 and gave the stock an equal weight rating in a research note on Friday, August 3rd. Finally, BMO Capital Markets set a $388.00 target price on Regeneron Pharmaceuticals and gave the stock a hold rating in a research note on Thursday, August 2nd. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $410.95.

Shares of NASDAQ:REGN traded up $2.34 during trading on Friday, hitting $354.93. 764,395 shares of the company were exchanged, compared to its average volume of 847,758. The firm has a market capitalization of $38.10 billion, a price-to-earnings ratio of 26.47, a price-to-earnings-growth ratio of 1.18 and a beta of 1.34. Regeneron Pharmaceuticals has a fifty-two week low of $281.89 and a fifty-two week high of $432.50. The company has a quick ratio of 2.92, a current ratio of 3.62 and a debt-to-equity ratio of 0.10.

In other news, major shareholder Sanofi sold 104,552 shares of the business’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael S. Brown sold 2,000 shares of the business’s stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $392.26, for a total value of $784,520.00. Following the transaction, the director now directly owns 2,000 shares of the company’s stock, valued at approximately $784,520. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 110,052 shares of company stock valued at $44,651,762. Corporate insiders own 12.42% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Skandinaviska Enskilda Banken AB publ raised its holdings in shares of Regeneron Pharmaceuticals by 118.7% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 95,629 shares of the biopharmaceutical company’s stock worth $38,638,000 after buying an additional 51,903 shares in the last quarter. Dupont Capital Management Corp acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $390,000. Cannell Peter B & Co. Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 40.2% during the 3rd quarter. Cannell Peter B & Co. Inc. now owns 45,863 shares of the biopharmaceutical company’s stock worth $18,530,000 after buying an additional 13,147 shares in the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Regeneron Pharmaceuticals by 23.7% during the 3rd quarter. Janney Montgomery Scott LLC now owns 5,616 shares of the biopharmaceutical company’s stock worth $2,269,000 after buying an additional 1,075 shares in the last quarter. Finally, Gulf International Bank UK Ltd raised its holdings in shares of Regeneron Pharmaceuticals by 7.9% during the 3rd quarter. Gulf International Bank UK Ltd now owns 27,065 shares of the biopharmaceutical company’s stock worth $10,935,000 after buying an additional 1,977 shares in the last quarter. 66.06% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Discount Rate

Related posts

Leave a Comment